Compare BRBI & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRBI | ADCT |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | Brazil | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.9M | 192.7M |
| IPO Year | 2025 | 2019 |
| Metric | BRBI | ADCT |
|---|---|---|
| Price | $8.29 | $1.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 8.9K | ★ 1.2M |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | ★ 4.83% | N/A |
| EPS Growth | N/A | ★ 30.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.70 | $25.89 |
| P/E Ratio | $11.72 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $6.80 | $0.78 |
| 52 Week High | $16.61 | $4.98 |
| Indicator | BRBI | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 40.28 | 42.27 |
| Support Level | $6.87 | $0.97 |
| Resistance Level | $9.00 | $1.45 |
| Average True Range (ATR) | 0.72 | 0.17 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 45.00 | 8.00 |
BRBI BR Partners SA, formerly BR Advisory Partners Participacoes SA, is engaged in investing in other companies, domestic or foreign, as a partner, quota holder, or shareholder, and management of its assets. It has a single reportable segment being investment banking services, which are administered and managed according to the products offered. However, the company divides it's operations into the following business lines: (1) investment banking and capital markets, (2) treasury sales & structuring, (3) investments and wealth management and (4) capital remuneration.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).